Favaro JP - Search Results

1

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.

Ryan P, McBride A, Ray D, Pulgar S, Ramirez RA, Elquza E, Favaro JP, Dranitsaris G. Ryan P, et al. Among authors: favaro jp. J Oncol Pharm Pract. 2019 Sep;25(6):1425-1433. doi: 10.1177/1078155219839458. Epub 2019 Mar 29. J Oncol Pharm Pract. 2019. PMID: 30924737 Free PMC article.

2

A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.

Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, Hurwitz HI. Uronis HE, et al. Oncologist. 2013;18(3):271-2. doi: 10.1634/theoncologist.2012-0404. Epub 2013 Mar 13. Oncologist. 2013. PMID: 23485624 Free PMC article. Clinical Trial.

3

Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.

Hurwitz HI, Honeycutt W, Haley S, Favaro J. Hurwitz HI, et al. Clin Colorectal Cancer. 2006 May;6(1):66-9. doi: 10.3816/CCC.2006.n.023. Clin Colorectal Cancer. 2006. PMID: 16796794

4

A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.

Dugan E, Truax R, Meadows KL, Nixon AB, Petros WP, Favaro J, Fernando NH, Morse MA, Blobe GC, Hurwitz HI. Dugan E, et al. Anticancer Res. 2010 Apr;30(4):1251-6. Anticancer Res. 2010. PMID: 20530436 Free PMC article. Clinical Trial.

5

Targeted therapy in renal cell carcinoma.

Favaro JP, George DJ. Favaro JP, et al. Expert Opin Investig Drugs. 2005 Oct;14(10):1251-8. doi: 10.1517/13543784.14.10.1251. Expert Opin Investig Drugs. 2005. PMID: 16185167 Review.

6

Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.

Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, Kimmick GG, Favaro J, Hamilton E, Welch RA, Bacus S, Blackwell KL. Herold CI, et al. Clin Cancer Res. 2011 Sep 15;17(18):6061-70. doi: 10.1158/1078-0432.CCR-11-1071. Epub 2011 Aug 2. Clin Cancer Res. 2011. PMID: 21810917 Clinical Trial.

7

Effect of rev on the cytoplasmic localization of intron-containing human immunodeficiency virus type 1 RNA.

Favaro JP, Maldarelli F, Arrigo SJ, Schmidt MG. Favaro JP, et al. Virology. 1999 Mar 15;255(2):237-49. doi: 10.1006/viro.1998.9584. Virology. 1999. PMID: 10069949 Free article.

8

Activation of a cryptic splice donor in human immunodeficiency virus type-1.

Borg KT, Favaro JP, Arrigo SJ, Schmidt M. Borg KT, et al. Among authors: favaro jp. J Biomed Sci. 1999 Jan;6(1):45-52. doi: 10.1007/BF02256423. J Biomed Sci. 1999. PMID: 9933742

9

Effect of Rev on the intranuclear localization of HIV-1 unspliced RNA.

Favaro JP, Borg KT, Arrigo SJ, Schmidt MG. Favaro JP, et al. Virology. 1998 Sep 30;249(2):286-96. doi: 10.1006/viro.1998.9312. Virology. 1998. PMID: 9791020 Free article.

10

Involvement of human immunodeficiency virus type-1 splice sites in the cytoplasmic accumulation of viral RNA.

Borg KT, Favaro JP, Arrigo SJ. Borg KT, et al. Among authors: favaro jp. Virology. 1997 Sep 15;236(1):95-103. doi: 10.1006/viro.1997.8726. Virology. 1997. PMID: 9299621 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page